Study of serum lipid profile and serum lipo-protein (a) in type II diabetes mellitus patients compared to non-diabetics


  • J. Prathyusha Rao Department of General Medicine, Bhaskar Medical College, Yenkapally, Moinabad, Telangana, India
  • Abhinav Thota Department of Dr. Patnam Mahender Reddy Institute of Medical Sciences, Chevella, Telangana, India



Lipid profile, Diabetes, Insulin, ECG, 2D echo


Background: This study helps us in evaluating present Indian scenario of lipid and diabetic portfolio, and advices about how aggressive treatment should be for immediate control of blood sugars and lipids are to minimize the cardiovascular risks. The objective of this study was to evaluate the serum lipid profile and lipo-protein (a) levels in comparison to patients with type II diabetics with non-diabetics.

Methods:It was a hospital-based case control study conducted on patients presenting with signs and symptoms of diabetes mellitus and confirmed on doing appropriate investigation. 200 patients of which 100 were non-diabetic (control) and 100 type II diabetic patients, of which fifty were type II diabetics were on oral hypoglycemic agents (OHA) and 50 were on insulin only, were selected after matching for age and sex. Lipid profile, serum lipoprotein (a), ECG, 2D echo was studied in these patients.

Results: The males were more (74%) than females (26%) among the cases. Fasting blood sugar, post prandial blood sugar and HbA1c were significantly more in cases. Triglycerides, LDL, VLDL and lipoprotein (a) were significantly more in cases. ST shift (mm) and T wave inversions were significantly more in cases compared to controls (p<0.05). Mean ejection fraction was significantly reduced in cases compared to controls. FBS and PPBS were not significantly different in two groups of OHA and insulin but HbA1c was significantly better controlled in insulin group than OHA group.

Conclusions:Lipid profile and lipoprotein (a) as well as ECG and 2D echo parameters were significantly worse in diabetes patients. Hence appropriate management is important to prevent risk of complications.


Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782-7.

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4-14.

Shlomo M, Williams RH. Williams Textbook of Endocrinology. 12th ed. Philadelphia: Elsevier/Saunders; 2011.

Chaturvedi N, Fuller JH, Taskinen MR, Eurodiab PCS Group. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care. 2001;24(12):2071-7.

Mazzone T. Current concepts and controversies in the pathogenesis, prevention, and treatment of the macrovascular complications of diabetes. J Lab Clin Med. 2000;135(6):437-43.

Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3(2):463-524.

Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ. 1989;299(6708):1127-31.

Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322(24):1700-7.

Rosengren A, Hagman M, Wedel H, Wilhelmsen L. Serum cholesterol and long-term prognosis in middle-aged men with myocardial infarction and angina pectoris. A 16-year follow-up of the Primary Prevention Study in Göteborg, Sweden. Eur Heart J. 1997;18(5):754-61.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269(23):3015-23.

Management of dyslipidemia in adults with diabetes. American Diabetes Association. Diabetes Care. 1998;21(1):179-82.

Bagdade JD, Porte D, Bierman EL. Diabetic lipemia. A form of acquired fat-induced lipemia. N Engl J Med. 1967;276(8):427-33.

Nikkila EA, Hormila P. Serum lipids and lipoproteins in insulin-treated diabetes. Demonstration of increased high density lipoprotein concentrations. Diabetes. 1978;27(11):1078-86.

Kennedy L, Walshe K, Hadden DR, Weaver JA, Buchanan KD. The effect of intensive dietary therapy on serum high density lipoprotein cholesterol in patients with Type 2 (non-insulin-dependent) diabetes mellitus: a prospective study. Diabetologia. 1982;23(1):24-7.

Otamere HO. Lipid Profile in Diabetes Mellitus; What Impact Has Age and Duration. Br J Pharmacol Toxicol. 2011;2(3):135-7.

Rani HS, Madhavi G, Rao VR, Sahay BK, Jyothy A. Risk factors for coronary heart disease in type II diabetes mellitus. Indian J Clin Biochem. 2005;20(2):75-80.

Haffner SM. Lipoprotein(a) and diabetes. An update. Diabetes Care. 1993;16(5):835-40.

Fujino A, Watanabe T, Kunii H, Yamaguchi N, Yoshinari K, Watanabe Y, et al. Lipoprotein(a) is a potential coronary risk factor. Jpn Circ J. 2000;64(1):51-6.

Bewu AD, Durrington PN, Mackness MI, Hunt L, Turkie WH, Creamer JE. Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction. Br Heart J. 1994;71(4):316-21.

Keidan B, Hsia J, Katz R. Plasma Lipids and anti-diabetic agents-a brief overview. British J Diab Vasc Dis. 2002;2:40-3.






Original Research Articles